id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-261827-uprv8a2k	Brodszki, Nicholas	Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions	2016-01-15		.txt	text/plain	4395	228	54	title: Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for severe combined immunodeficiency (SCID); although, there is a high incidence of severe infections and an increased risk of graft-versus host-disease (GvHD) with HSCT. Haploidentical HSCT protocols utilizing extensively ex vivo T-cell depleted grafts (CliniMACs system) have proven efficient in preventing GvHD, but cause a delay in early T-cell recovery that increases the risk of viral infections. Here, we present a novel approach for treating SCID that combines selective depletion of GvHD-inducing alpha/beta (α/β) T-cells from the haploidentical HSCT graft with a subsequent donor lymphocyte infusion (DLI) enriched for CD45RO+ memory T-cells. Unselected donor lymphocyte infusions (DLIs), which are frequently used as a "tool" to boost anti-viral immunity post-transplant, harbor a significant risk of inducing severe GvHD in the haploidentical setting [6, 7] .	./cache/cord-261827-uprv8a2k.txt	./txt/cord-261827-uprv8a2k.txt